[26]
Mr. Windross also gave evidence that he felt protecting the confidentiality of submissions is a cornerstone of the drug approval process and that allowing third parties to interfere with that protection would have a negative effect on the pharmaceutical industry as a whole.
4. POINTS IN ISSUE